BidaskClub upgraded shares of GALAPAGOS NV/S (NASDAQ:GLPG) from a hold rating to a buy rating in a research note released on Friday morning.
GLPG has been the topic of a number of other research reports. Nomura increased their price target on GALAPAGOS NV/S from $124.00 to $140.00 and gave the stock a buy rating in a research report on Tuesday, October 30th. Zacks Investment Research downgraded GALAPAGOS NV/S from a buy rating to a hold rating in a research report on Friday, October 12th. Raymond James started coverage on GALAPAGOS NV/S in a research report on Wednesday, November 14th. They set a strong-buy rating and a $157.00 price target on the stock. ValuEngine raised GALAPAGOS NV/S from a buy rating to a strong-buy rating in a research report on Saturday, November 10th. Finally, Morgan Stanley increased their price target on GALAPAGOS NV/S from $127.00 to $131.00 and gave the stock an overweight rating in a research report on Monday, November 5th. Two investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. The stock has a consensus rating of Buy and a consensus price target of $122.00.
GLPG opened at $104.45 on Friday. GALAPAGOS NV/S has a 12-month low of $85.00 and a 12-month high of $122.28. The firm has a market cap of $5.41 billion, a PE ratio of -39.56 and a beta of 1.74.
Hedge funds have recently modified their holdings of the stock. Federated Investors Inc. PA raised its stake in GALAPAGOS NV/S by 17.8% in the third quarter. Federated Investors Inc. PA now owns 1,677,922 shares of the biotechnology company’s stock valued at $188,648,000 after buying an additional 253,159 shares during the last quarter. BlackRock Inc. raised its stake in shares of GALAPAGOS NV/S by 18.4% in the third quarter. BlackRock Inc. now owns 365,413 shares of the biotechnology company’s stock worth $41,083,000 after purchasing an additional 56,848 shares during the last quarter. Credit Suisse AG raised its stake in shares of GALAPAGOS NV/S by 52.0% in the third quarter. Credit Suisse AG now owns 190,376 shares of the biotechnology company’s stock worth $21,404,000 after purchasing an additional 65,094 shares during the last quarter. Jane Street Group LLC raised its stake in shares of GALAPAGOS NV/S by 214.1% in the third quarter. Jane Street Group LLC now owns 185,269 shares of the biotechnology company’s stock worth $20,830,000 after purchasing an additional 126,277 shares during the last quarter. Finally, Laurion Capital Management LP purchased a new position in shares of GALAPAGOS NV/S in the third quarter worth about $19,841,000. 18.13% of the stock is currently owned by institutional investors.
GALAPAGOS NV/S Company Profile
Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes novel medicines. Its clinical stage programs include filgotinib, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and Crohn's disease, Phase 2/3 trials for ulcerative colitis, and Phase II trials for multiple additional indications; GLPG1690, an autotaxin inhibitor, which is in Phase III clinical trial for the treatment of idiopathic pulmonary fibrosis; GLPG1972 that completed Phase 1b clinical trial for the treatment of osteoarthritis; and MOR106, which is in Phase II trials for atopic dermatitis patients.
Further Reading: How to Invest in a Bull Market
Receive News & Ratings for GALAPAGOS NV/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GALAPAGOS NV/S and related companies with MarketBeat.com's FREE daily email newsletter.